相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration
Taras Ardan et al.
DISEASE MODELS & MECHANISMS (2020)
Longitudinal study revealing motor, cognitive and behavioral decline in a transgenic minipig model of Huntington's disease
Monika Baxa et al.
DISEASE MODELS & MECHANISMS (2020)
GPR108 Is a Highly Conserved AAV Entry Factor
Amanda M. Dudek et al.
MOLECULAR THERAPY (2020)
Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders
M. M. J. van den Berg et al.
PROGRESS IN NEUROBIOLOGY (2020)
Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone
Ryan Reshke et al.
NATURE BIOMEDICAL ENGINEERING (2020)
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease
Yaping Chu et al.
BRAIN (2020)
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Jens Kuhle et al.
NEUROLOGY (2019)
AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models
Elisabeth A. Spronck et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
NFL is a marker of treatment response in children with SMA treated with nusinersen
Bob Olsson et al.
JOURNAL OF NEUROLOGY (2019)
Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease (vol 101, pg 801, 2019)
Sarah J. Tabrizi et al.
NEURON (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington's disease
Marie Rodinova et al.
DISEASE MODELS & MECHANISMS (2019)
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease
Bryan Zeitler et al.
NATURE MEDICINE (2019)
Gene Therapy Tools for Brain Diseases
Selene Ingusci et al.
FRONTIERS IN PHARMACOLOGY (2019)
A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system
Julia F. Alterman et al.
NATURE BIOTECHNOLOGY (2019)
Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics
Lisa M. Stanek et al.
NEUROBIOLOGY OF DISEASE (2019)
AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes
Sonay Keskin et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Huntington's disease: a clinical review
P. McColgan et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease
Edith L. Pfister et al.
HUMAN GENE THERAPY (2018)
Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic
Jana Miniarikova et al.
MOLECULAR THERAPY (2018)
AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model
Melvin M. Evers et al.
MOLECULAR THERAPY (2018)
Gradual Phenotype Development in Huntington Disease Transgenic Minipig Model at 24 Months of Age
Daniela Vidinska et al.
NEURODEGENERATIVE DISEASES (2018)
Gene therapy for neurological disorders: progress and prospects
Benjamin E. Deverman et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease
Lauren M. Byrne et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain
L. Samaranch et al.
GENE THERAPY (2017)
AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease
J. Miniarikova et al.
GENE THERAPY (2017)
Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
Lauren M. Byrne et al.
LANCET NEUROLOGY (2017)
Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5ch and AAV1
Anna Majowicz et al.
MOLECULAR THERAPY (2017)
Mitochondrial Metabolism in a Large-Animal Model of Huntington Disease: The Hunt for Biomarkers in the Spermatozoa of Presymptomatic Minipigs
Jana Krizova et al.
NEURODEGENERATIVE DISEASES (2017)
Viral vectors for therapy of neurologic diseases
Sourav R. Choudhury et al.
NEUROPHARMACOLOGY (2017)
Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis
Paula Dietrich et al.
PLOS GENETICS (2017)
Safe and Efficient Silencing with a Pol II, but Not a Pol III, Promoter Expressing an Artificial miRNA Targeting Human Huntingtin
Edith L. Pfister et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay
Valentina Fodale et al.
JOURNAL OF HUNTINGTONS DISEASE (2017)
Huntington's Disease-Update on Treatments
Kara J. Wyant et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2017)
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia
Megan S. Keiser et al.
HUMAN MOLECULAR GENETICS (2016)
Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease
Jana Miniarikova et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients
Edward J. Wild et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Evaluation of the Expression Pattern of rAAV2/1, 2/5, 2/7, 2/8, and 2/9 Serotypes With Different Promoters in the Mouse Visual Cortex
Isabelle Scheyltjens et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2015)
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
Jens Kuhle et al.
NEUROLOGY (2015)
Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression
Amber L. Southwell et al.
SCIENTIFIC REPORTS (2015)
Huntington disease
Gillian P. Bates et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex
Annelies Gerits et al.
NEUROPHOTONICS (2015)
Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease
Lisa M. Stanek et al.
HUMAN GENE THERAPY (2014)
Huntington disease: natural history, biomarkers and prospects for therapeutics
Christopher A. Ross et al.
NATURE REVIEWS NEUROLOGY (2014)
Titer and Product Affect the Distribution of Gene Expression after Intraputaminal Convection-Enhanced Delivery
Marina E. Emborg et al.
STEREOTACTIC AND FUNCTIONAL NEUROSURGERY (2014)
Convection-enhanced delivery of AAV2 in white matter-A novel method for gene delivery to cerebral cortex
N. U. Barua et al.
JOURNAL OF NEUROSCIENCE METHODS (2013)
A Transgenic Minipig Model of Huntington's Disease
Monika Baxa et al.
JOURNAL OF HUNTINGTONS DISEASE (2013)
Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types
Jasenka Guduric-Fuchs et al.
BMC GENOMICS (2012)
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
Richard Grondin et al.
BRAIN (2012)
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Gabriele Mittermeyer et al.
HUMAN GENE THERAPY (2012)
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates
Carmen Unzu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Holly B. Kordasiewicz et al.
NEURON (2012)
Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson's disease
R. Constantinescu et al.
ACTA NEUROLOGICA SCANDINAVICA (2011)
Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
Jodi L. McBride et al.
MOLECULAR THERAPY (2011)
An optogenetic toolbox designed for primates
Ilka Diester et al.
NATURE NEUROSCIENCE (2011)
Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate
Marie-Anne Colle et al.
HUMAN MOLECULAR GENETICS (2010)
An ovine transgenic Huntington's disease model
Jessie C. Jacobsen et al.
HUMAN MOLECULAR GENETICS (2010)
Comparative Transduction Efficiency of AAV Vector Serotypes 1-6 in the Substantia Nigra and Striatum of the Primate Brain
Eleni A. Markakis et al.
MOLECULAR THERAPY (2010)
Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADC
Piotr Hadaczek et al.
MOLECULAR THERAPY (2010)
Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease
Radu Constantinescu et al.
PARKINSONISM & RELATED DISORDERS (2009)
Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection
A. Mellgren et al.
NEUROLOGY (2007)
Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain
Jean-Marc Taymans et al.
HUMAN GENE THERAPY (2007)
The use of pigs in neuroscience: Modeling brain disorders
Nanna Marie Lind et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2007)
AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL
D Sondhi et al.
GENE THERAPY (2005)
Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system
C Burger et al.
MOLECULAR THERAPY (2004)
Insect cells as a factory to produce adeno-associated virus type 2 vectors
M Urabe et al.
HUMAN GENE THERAPY (2002)
分享论文
